Deltex Medical Group PLC CardioQ-ODM+ wins Paris Hospital System Tender (3226F)
February 20 2018 - 1:00AM
UK Regulatory
TIDMDEMG
RNS Number : 3226F
Deltex Medical Group PLC
20 February 2018
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014
("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
20 February 2018
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
CardioQ-ODM+ wins Paris Hospital System tender
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that
its French distributor has been awarded a new tender to supply
hospitals in Paris with CardioQ-ODM+ equipment.
The Company's French distribution partner, Gamida SA ("Gamida"),
has won an eight year tender to supply CardioQ-ODM+ products to the
Assistance Hopitaux Publique de Paris ('AHPP'). AHPP is the public
hospital system of the city of Paris and its suburbs. It includes
over 40 hospitals and is linked to the University of Paris. The
tender is for a total of not less than 34,000 disposable probes and
has a minimum value of over EUR4m over the eight year tender.
The terms of the tender, which replaces a previous tender
originally awarded in 2011 and extended in 2014, requires Gamida to
supply 70 new CardioQ-ODM+ monitors free of charge to AHPP
hospitals. Deltex is supporting this requirement by supplying the
monitors at very low margin and has this month received orders of
GBP0.1m for 50 monitor systems, with the remaining 20 monitors to
be supplied out of Gamida's own inventory.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"This is the largest value tender ever awarded anywhere for the
Company's products and consolidates our strong market position in
France, especially in Paris. France is our largest export market by
volume and second only to the USA by value."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments 0203 621 4120
(TPI) Ltd info@turnerpope.com
Andy Thacker
Financial Public Relations
IFC Advisory Ltd 0203 934 6632
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM is the only
technology to measure blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM which is proven
to reduce complications suffered by patients after surgery and save
hospitals the costs of treating those complications.
Deltex Medical's CardioQ-ODM+ platform also now provides
clinicians with two further advanced haemodynamic monitoring
technologies. High Definition Impedance Cardiography is an entirely
non-invasive monitoring technology which creates an electrical
field across the chest and measures the disruption to this field
when the heart pumps blood. Pulse Pressure Waveform Analysis uses
peripheral blood pressure signal analysis to give doctors
information on changes in the circulation and is particularly
suited to monitoring lower risk or haemodynamically stable
patients.
Company goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Company's
focus is on maximising value from the opportunities presented as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Company aims to provide clinicians
with a single platform, a 'haemodynamic workstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition and skill and
expertise of the user. Doing this will enable the Company to
partner healthcare providers to support modern haemodynamic
management across the whole hospital.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFITFFIALIT
(END) Dow Jones Newswires
February 20, 2018 02:00 ET (07:00 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024